Treating adrenal cancer with an ACAT1 inhibitor
This article was originally published in Start Up
Atterocor Inc. aims to destroy, or at least interfere with, pathological processes in cortical cells of the adrenal glands. The start-up has secured orphan designation and initiated Phase I trials on a compound it calls ATR-101, a novel ACAT1 inhibitor that induces apoptosis, in people with adrenocortical carcinoma, or adrenal cancer, a truly rare and fatal disease.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.